A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zamalintinib (XL092) in Combination with Pembrolizumab Vs Pembrolizumab in the First-Line Treatment of Subjects with Pd-LI Positive Recurrent

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Ricklie Julian
Sponsor
IQVIA RDS Inc.
Unit
Cancer Center Division